2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

ADC-Related Custom Services

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-152916
    mp-dLAE-PABC-MMAE
    mp-dLAE-PABC-MMAE is a agent-linker conjugate for ADC. mp-dLAE-PABC-MMAE contains a potent tubulin inhibitor Monomethyl auristatin E (HY-15162). mp-dLAE-PABC-MMAE can be used to synthesis antibody-drug conjugates (ADCs).
    mp-dLAE-PABC-MMAE
  • HY-147286A
    Ac-Lys-Val-Cit-PABC-MMAE formic
    		99.96%
    Ac-Lys-Val-Cit-PABC-MMAE (formic) is a agent-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor auristatin E.html" class="link-product" target="_blank"> Monomethyl auristatin E (HY-15162).
    Ac-Lys-Val-Cit-PABC-MMAE formic
  • HY-156515
    MC-GGFG-(7ethanol-10NH2-11F-Camptothecin)
    MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) (compound 141) is a drug-linker conjugates for ADC. MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) is a MC-GGFG-(7ethanol-10NH2-11F-Camptothecin) with protease cleavable MC-GGFG linker.
    MC-GGFG-(7ethanol-10NH2-11F-Camptothecin)
  • HY-128942
    MAC glucuronide α-hydroxy lactone-linked SN-38
    MAC glucuronide α-hydroxy lactone-linked SN-38 (Topoisomerase I inhibitor) is a stabilized lactone MAC glucuronide α-hydroxy lactone-linked SN-38 agent linker. MAC glucuronide α-hydroxy lactone-linked SN-38 is cytotoxic across L540cy cells and Ramos cells with IC50 values of 99 and 105 ng/mL, respectively.
    MAC glucuronide α-hydroxy lactone-linked SN-38
  • HY-126693
    SC-VC-PAB-DM1
    SC-VC-PAB-DM1 is a agent-linker conjugate for ADC with with potent antitumor activity by using DM1 (Mertansine, a tubulin inhibitor) , linked via the ADC linker SC-VC-PAB.
    SC-VC-PAB-DM1
  • HY-136260
    DBCO-PEG4-Ahx-DM1
    DBCO-PEG4-Ahx-DM1 is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DBCO-PEG4-Ahx-DM1 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-Ahx-DM1
  • HY-128959
    MCC-Modified Daunorubicinol
    MCC-Modified Daunorubicinol is a drug-Linker conjugates for ADC, which is composed of Modified Daunorubicinol (DNA topoisomerase II inhibitor) and MCC (ADC linker) linked.
    MCC-Modified Daunorubicinol
  • HY-148871
    Mc-Val-Cit-PAB-Gefitinib chloride
    		98.69%
    Mc-Val-Cit-PAB-Gefitinib chloride is a agent-linker conjugates for ADC. Mc-Val-Cit-PAB-Gefitinib chloride consists of Gefitinib (HY-50895) (an EGFR tyrosine kinase inhibitor) and the ADC linker Mc-Val-Cit-PAB.
    Mc-Val-Cit-PAB-Gefitinib chloride
  • HY-150402
    MC-Gly-Gly-Phe-Gly-amide-cyclopropanol-amide-Exatecan
    		99.16%
    MC-Gly-Gly-Phe-Gly-amide-cyclopropanol-amide-Exatecan is a pharmaceutical composition containing antibody agent conjugate (ADC). (extracted from patent WO2021190581 Example 1-8).
    MC-Gly-Gly-Phe-Gly-amide-cyclopropanol-amide-Exatecan
  • HY-168489
    OBI-992 drug-linker
    OBI-992 drug-linker is a drug-linker conjugate composed of a TOP I inhibitor Exatecan (HY-13631) and a linker. OBI-992 drug-linker exhibits antitumor property in mouse models and can be used for synthesis of ADC OBI-992.
    OBI-992 drug-linker
  • HY-170587
    Glucocorticoid receptor drug-linke 1
    Glucocorticoid receptor drug-linke 1 is a drug-linker conjugate, that can be used for synthesis of BDCA2-targeting ADC.
    Glucocorticoid receptor drug-linke 1
  • HY-153962
    SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3
    SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a Drug-Linker Conjugate for ADC. SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 consists of the anti-cancer agent SN38 (HY-13704) and a linker Lys(MMT)-PAB-oxydiacetamide-PEG8-N3 (HY-131157). SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 can be used for synthesis of ADCs. SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3
  • HY-128907
    MC-Val-Cit-PAB-clindamycin
    		99.99%
    MC-Val-Cit-PAB-clindamycin is a agent-linker conjugate for ADC with potent antitumor activity by using clindamycin (a protein synthesis inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
    MC-Val-Cit-PAB-clindamycin
  • HY-158768
    Amino-PEG4-GGFG-Dxd
    		99.95%
    Amino-PEG4-GGFG-Dxd (Compound 13-7) is a drug-linker conjugate for ADC. Amino-PEG4-GGFG-Dxd is composed of Dxd (HY-13631D) and a linker. Amino-PEG4-GGFG-Dxd can be used for synthesis of ADCs
    Amino-PEG4-GGFG-Dxd
  • HY-164995
    L1BC8
    L1BC8 (compound 13a) is a BRD4 PROTAC degrader with anticancer effects. L1BC8 is also a drug-linker conjugate for ADC that can be used for the synthesis of ADCs. The resulting BRD4-degrader antibody conjugates exhibit potent and antigen-dependent BRD4 degradation and antiproliferation activities in cell-based experiments. (Pink: BRD4 ligand (HY-129939); Blue: VHL ligand (HY-125845); Black: linker (HY-171663)).
    L1BC8
  • HY-141596
    Lys-Nε-SPDB-DM4
    		99.81%
    Lys-Nε-SPDB-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Lys-Nε-SPDB to make antibody agent conjugate (ADC).
    Lys-Nε-SPDB-DM4
  • HY-145989
    Aminobenzenesulfonic auristatin E
    Aminobenzenesulfonic auristatin E is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic.
    Aminobenzenesulfonic auristatin E
  • HY-164637
    Aniline-PEG3-C1-Boc
    Aniline-PEG3-C1-Boc (compound D-1) is an intermediate of cytotoxic drug linker polymer. Aniline-PEG3-C1-Boc can be used in the synthesis of antibody-drug conjugates (ADCs).
    Aniline-PEG3-C1-Boc
  • HY-148346
    STING agonist-20-Ala-amide-PEG2-C2-NH2
    STING agonist-20-Ala-amide-PEG2-C2-NH2 is an active scaffold comprising a stimulator of interferon genes (STING). STING agonist-20-Ala-amide-PEG2-C2-NH2 can be used to synthesize immune-stimulating antibody conjugate (ISAC). STING agonist-20-Ala-amide-PEG2-C2-NH2 can be used for the research of cancer.
    STING agonist-20-Ala-amide-PEG2-C2-NH2
  • HY-155870
    DL-01
    DL-01 is a drug-linker conjugates for ADC that can be used for the synthesis of ADCs.
    DL-01
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.